Orange Book product · Generic (ANDA)
LIDOCAINE
LIDOCAINE
At a glance
Mar 25, 2025
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 25, 2025
1 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
LIDOCAINE
Strength
1.8%
Dosage form
PATCH
Route
TOPICAL
TE code
AB
Application
ANDA 217221
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LIDOCAINE
- 2025BONDLIDOBrand (NDA)
NDA 215029 · MEDRX USA
- 2018ZTLIDOBrand (NDA)
NDA 207962 · SCILEX PHARMS
- 1999LIDODERMBrand (NDA)
NDA 020612 · TEIKOKU PHARMA USA
- 1996DENTIPATCHBrand (NDA)
NDA 020575 · NOVEN
- —XYLOCAINEBrand (NDA)
NDA 014394 · ASTRAZENECA
- —XYLOCAINEBrand (NDA)
NDA 008048 · ASTRAZENECA
- —XYLOCAINEBrand (NDA)
NDA 014127 · ASTRAZENECA
- —XYLOCAINEBrand (NDA)
NDA 013077 · ASTRAZENECA
- 2026LIDOCAINEGeneric (ANDA)
ANDA 207059 · USPHARMA
- 2025LIDOCAINEGeneric (ANDA)
ANDA 216484 · ALKEM LABS LTD
- 2024LIDOCAINEGeneric (ANDA)
ANDA 217117 · AUROBINDO PHARMA LTD
- 2021LIDOCAINEGeneric (ANDA)
ANDA 205882 · NAL PHARM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
